In this issue:
Adagrasib ± cetuximab has antitumour activity in KRAS-mutated mCRC
Front-line TAS-102 combo for unresectable disease not suited for intensive therapy
Neoadjuvant chemotherapy may negate need for TME in early-stage rectal cancer
Physical activity linked to prolonged DFS in stage 3 colon cancer
Cytoreductive surgery + HIPEC for peritoneal metastases feasible at any age
REARRANGE: initial reduced-dose regorafenib may improve tolerability
Liquid biopsy predicts benefit to front-line anti-EGFR treatment
CRT + local excision vs TME for T2/3N0/M0 rectal cancer
Survival after focal ablative therapy for CRC liver metastases
Activity of pyrotinib and trastuzumab in refractory HER2 positive disease
Please login below to download this issue (PDF)